RhumbLine Advisers’s Immunovant IMVT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.62M | Buy |
101,381
+17,826
| +21% | +$285K | ﹤0.01% | 1995 |
|
|
2025
Q1 | $1.43M | Buy |
83,555
+2,623
| +3% | +$44.8K | ﹤0.01% | 1989 |
|
|
2024
Q4 | $2M | Buy |
80,932
+1,188
| +1% | +$29.4K | ﹤0.01% | 1871 |
|
|
2024
Q3 | $2.27M | Sell |
79,744
-3,788
| -5% | -$108K | ﹤0.01% | 1833 |
|
|
2024
Q2 | $2.21M | Buy |
83,532
+7,363
| +10% | +$194K | ﹤0.01% | 1833 |
|
|
2024
Q1 | $2.46M | Buy |
76,169
+1,810
| +2% | +$58.5K | ﹤0.01% | 1799 |
|
|
2023
Q4 | $3.13M | Sell |
74,359
-206
| -0.3% | -$8.68K | ﹤0.01% | 1675 |
|
|
2023
Q3 | $2.86M | Buy |
74,565
+2,367
| +3% | +$90.9K | ﹤0.01% | 1666 |
|
|
2023
Q2 | $1.37M | Buy |
72,198
+550
| +0.8% | +$10.4K | ﹤0.01% | 2130 |
|
|
2023
Q1 | $1.11M | Buy |
71,648
+1,806
| +3% | +$28K | ﹤0.01% | 2073 |
|
|
2022
Q4 | $1.24M | Buy |
69,842
+7,460
| +12% | +$132K | ﹤0.01% | 2026 |
|
|
2022
Q3 | $348K | Buy |
62,382
+4,207
| +7% | +$23.5K | ﹤0.01% | 2664 |
|
|
2022
Q2 | $227K | Buy |
58,175
+12,711
| +28% | +$49.6K | ﹤0.01% | 2882 |
|
|
2022
Q1 | $251K | Sell |
45,464
-25
| -0.1% | -$138 | ﹤0.01% | 2696 |
|
|
2021
Q4 | $388K | Sell |
45,489
-601
| -1% | -$5.13K | ﹤0.01% | 2617 |
|
|
2021
Q3 | $401K | Buy |
46,090
+1,880
| +4% | +$16.4K | ﹤0.01% | 2644 |
|
|
2021
Q2 | $467K | Buy |
44,210
+2,252
| +5% | +$23.8K | ﹤0.01% | 2594 |
|
|
2021
Q1 | $673K | Sell |
41,958
-1,755
| -4% | -$28.2K | ﹤0.01% | 2360 |
|
|
2020
Q4 | $2.02M | Buy |
43,713
+5,963
| +16% | +$275K | ﹤0.01% | 1838 |
|
|
2020
Q3 | $1.33M | Buy |
37,750
+14,849
| +65% | +$522K | ﹤0.01% | 1881 |
|
|
2020
Q2 | $558K | Buy |
+22,901
| New | +$558K | ﹤0.01% | 2294 |
|